NasdaqHealth CareHealth Care EquipmentS&P 500Nasdaq-100
$676.04
+5.33 (+0.79%)
Close of Nov 06, 2026 · end-of-day data
IDXX 8-K filings, explained
Every material Form 8-K Idexx Laboratories has filed with the SEC since December 12, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IDEXX Laboratories announced third-quarter revenue of $1,214 million and diluted earnings per share of $4.01, representing solid year-over-year gains. Driven by strong Companion Animal Group performance and innovation adoption, the company raised its full-year 2026 revenue and EPS outlook for shareholders.
Third-quarter revenue reached $1,214 million, up 10% as reported and organic.
Diluted earnings per share were $4.01, an increase of 18% as reported.
Full-year 2026 revenue guidance was updated to a range of $4,741 million to $4,767 million.
Full-year 2026 EPS outlook was raised to $14.96 to $15.16.
IDEXX reported second quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organic, and diluted EPS of $4.27, up 18%. The company raised its 2026 EPS outlook to $14.69 to $14.94 from $14.45 to $14.90 and narrowed its full-year revenue guidance to $4,700 million to $4,745 million, which is $5 million higher at the midpoint.
Q2 revenue of $1,217 million, up 10% as reported and 9% organic; CAG Diagnostics recurring revenue up 11% as reported
Q2 EPS of $4.27, up 18% as reported and 15% comparable; includes $0.14 per share from share-based compensation tax benefits and $0.06 from currency
2026 EPS outlook raised to $14.69 to $14.94, from $14.45 to $14.90 previously
Q2 operating margin of 35.0%, up 140 basis points as reported; 1,600 IDEXX inVue Dx placements in the quarter
IDEXX reported first-quarter 2026 revenue of $1,141 million, up 14% as reported and 11% organic, and EPS of $3.47, up 17% as reported. The company raised its 2026 revenue guidance to $4,675 million to $4,760 million and its EPS outlook to $14.45 to $14.90, and said CEO Jay Mazelsky is transitioning from the CEO role.
Q1 2026 revenue $1,141 million, up 14% as reported and 11% organic; Companion Animal Group revenue up 15% as reported.
Q1 EPS $3.47, up 17% as reported and 15% comparable; included a $0.05 loss on an equity investment and a $0.14 currency benefit.
2026 revenue guidance raised to $4,675 million to $4,760 million; EPS outlook raised to $14.45 to $14.90 from $14.29 to $14.80.
Mazelsky said he is transitioning from the CEO role; the release says he will work with Mike Erickson on long-term growth.
IDEXX and Executive Vice President, Global Strategy and Commercial Nimrata Hunt agreed on March 24, 2026 that she will leave her role effective April 13, 2026, because her position is being eliminated. She will then provide advisory services until July 13, 2026, under a separation agreement that includes salary continuation and a two-year target bonus, and her unvested equity awards will be forfeited.
Separation Date April 13, 2026; advisory services continue until Final Employment Date July 13, 2026
Salary continuation for 104 weeks totaling $1,230,000, plus two years of target annual bonus totaling $984,000
Unvested stock option, RSU and PSU awards will be forfeited; a $50,000 COBRA lump sum and $10,000 transition benefit are also included
IDEXX Laboratories director M. Anne Szostak notified the company on February 13, 2026 that she will retire from the Board effective immediately after the 2026 Annual Meeting on May 12, 2026. The filing says her decision did not arise from any disagreement with the company or the Board, and the Board reduced the size of Class III upon her retirement without shrinking the overall Board, given the previously announced appointment of Michael G. Erickson, PhD, as a Class II member.
Director M. Anne Szostak, on the Board since 2012, will retire after the 2026 Annual Meeting on May 12, 2026
The filing states no disagreement with the company or Board on operations, policies or practices
Board reduced the size of Class III upon her retirement but kept overall Board size unchanged
Michael G. Erickson, PhD, previously announced, will join as a Class II member immediately after the 2026 Annual Meeting
IDEXX reported fourth quarter 2025 revenue of $1,091 million, up 14% as reported and 12% organic, and fourth quarter EPS of $3.08, up 18%. The company also gave initial 2026 guidance of $4,632 million to $4,720 million in revenue and $14.29 to $14.80 in EPS, which would represent reported EPS growth of 9% to 13%.
Q4 2025 revenue $1,091 million, up 14% as reported and 12% organic; CAG Diagnostics recurring revenue up 12% as reported
Q4 2025 EPS $3.08, up 18% as reported and 17% comparable; operating margin 28.9%, up 150 basis points as reported
Full-year 2025 revenue $4,304 million, up 10%; full-year EPS $13.08, up 23% as reported and 14% comparable
2026 outlook: revenue $4,632 million to $4,720 million; EPS $14.29 to $14.80; operating margin 32.0% to 32.5%
IDEXX Laboratories said Michael (Mike) Erickson, PhD, will become President and Chief Executive Officer on May 12, 2026, replacing Jonathan (Jay) Mazelsky, who will become Executive Chair of the Board. Mazelsky plans to retire from the company and the Board immediately after the annual shareholder meeting in May 2027, and Erickson will join the Board as a Class II Director.
Erickson, 52, has worked at IDEXX since 2011 and currently serves as Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine.
Erickson's letter agreement sets an annualized base salary of $1,000,000 and a bonus target of 120% of base salary, with an expected 2026 long-term equity award of not less than $7.8 million.
Mazelsky's letter agreement sets a base salary of $1,150,000 as Executive Chair, with an expected 2026 time-vesting restricted stock unit grant of not less than $8.275 million.
Lawrence D. Kingsley, the current independent Non-Executive Chair, will serve as independent Lead Director from the transition date.
On November 12, 2025, IDEXX Laboratories and its subsidiaries entered into Amendment No. 2 to its credit agreement with JPMorgan Chase Bank as administrative agent. The amendment extends the maturity of the $1.0 billion unsecured revolving credit facility to five years and provides for a term loan facility maturing in three years, giving the company longer-dated borrowing capacity. The filing does not state any amount drawn under the facilities.
Revolving credit facility of $1.0 billion extended to five years from the amendment closing date.
New term loan facility maturing three years from the closing date; the existing $250 million unsecured term loan is also referenced.
Credit agreement includes flexibility for up to $250 million in incremental revolving commitments and/or term loans.
Interest is priced at SOFR, CORRA, EURIBOR or other benchmark rates plus margins of 0.0% to 1.375% based on the consolidated leverage ratio.
IDEXX reported third quarter 2025 revenue of $1,105 million, up 13% as reported and 12% organic, and diluted EPS of $3.40, up 21%. The company raised its full-year 2025 revenue guidance to $4,270 million-$4,300 million and its EPS outlook to $12.81-$13.01, both signaling stronger expected results for shareholders.
Q3 2025 revenue of $1,105 million, up 13% as reported and 12% organic; CAG revenue up 14% and LPD up 17%.
Q3 diluted EPS of $3.40, up 21% as reported and 15% comparable; operating margin 32.1%, up 100 basis points.
2025 revenue guidance raised to $4,270 million-$4,300 million from $4,205 million-$4,280 million; EPS outlook raised to $12.81-$13.01 from $12.40-$12.76.
IDEXX Laboratories added Karen Peacock, former CEO of Intercom, as an independent Class I director effective October 6, 2025, and expanded its board from ten to eleven members. The filing describes her compensation and committee roles but reports no financial results or changes in company guidance.
Karen Peacock elected independent Class I director effective October 6, 2025; board increased from ten to eleven members
Peacock appointed to the Compensation and Talent Committee and Finance Committee
Her annual director equity grants will be made December 1, 2025, prorated from October 6, 2025 to the 2026 annual meeting
Expected to stand for stockholder election as a Class I director at the 2027 annual meeting
IDEXX Laboratories reported second-quarter 2025 revenue of $1,109 million, up 11% as reported and 9% organic, and diluted EPS of $3.63, up 49% as reported. The company raised its full-year 2025 revenue guidance to $4,205 million–$4,280 million and its EPS outlook to $12.40–$12.76, which shareholders will weigh against a prior-year litigation accrual that depressed the comparison base.
Q2 2025 revenue $1,109 million, up 11% as reported and 9% organic; comparable EPS $3.50, up 17%
Diluted EPS $3.63 included $0.07 from a discrete tax reserve release and $0.10 from share-based compensation tax benefits
2025 revenue guidance raised to $4,205 million–$4,280 million, up $90 million at midpoint; EPS outlook raised by $0.40 at midpoint to $12.40–$12.76
IDEXX Laboratories added Joseph L. (Jay) Hooley, former Chair and CEO of State Street Corporation, as an independent director effective July 10, 2025. The board expanded from nine to ten directors, and Mr. Hooley joined the Audit Committee and the Governance and Corporate Responsibility Committee. The filing reports no financial results or guidance changes; the appointment is a board governance change.
Joseph L. (Jay) Hooley elected as an independent Class III Director effective July 10, 2025
Board size increased from nine to ten directors; Class III seats increased from three to four
Appointed to the Audit Committee and Governance and Corporate Responsibility Committee
Director stock grants to Mr. Hooley scheduled for September 1, 2025, prorated to the 2026 annual meeting
IDEXX reported first-quarter 2025 revenue of $998 million, up 4% as reported and 5% organic, and diluted EPS of $2.96, up 5% as reported. The company raised its full-year 2025 revenue guidance to $4,095 million-$4,210 million and its EPS outlook to $11.93-$12.43, though part of the EPS gain came from a $0.08 litigation accrual adjustment.
Q1 2025 revenue was $998 million, up 4% as reported and 5% organic.
Diluted EPS was $2.96, up 5% as reported and 7% on a comparable basis, which excludes a $0.08 benefit from a discrete litigation expense accrual adjustment.
2025 revenue guidance was raised to $4,095 million-$4,210 million from $4,055 million-$4,170 million; EPS outlook rose to $11.93-$12.43 from $11.74-$12.24.
Organic revenue growth guidance of 6%-9% was maintained.
IDEXX Laboratories disclosed that director Dr. Asha Collins resigned from its Board of Directors effective immediately on February 13, 2025. The company said the resignation was not due to any disagreement over its operations, policies or practices, and it reduced the board size from ten to nine directors.
Dr. Asha Collins resigned from the Board effective immediately on February 13, 2025
The filing states the resignation was not due to any disagreement with the company on operations, policies or practices
IDEXX reported fourth quarter 2024 revenue of $954 million, up 6%, and EPS of $2.62, up 13% as reported. For the full year, revenue rose 6% to $3,898 million and EPS rose 6% to $10.67, after a $0.56 per share charge tied to an ongoing litigation matter. The company also issued initial 2025 guidance of $4,055 million to $4,170 million in revenue and $11.74 to $12.24 in EPS, and assumes about $1.5 billion of share repurchases.
Q4 2024 revenue of $954 million, up 6% as reported and organically; Q4 EPS of $2.62, up 13% as reported
Full year 2024 EPS of $10.67 included a $0.56 per share negative impact from a discrete litigation expense accrual
2025 outlook: revenue of $4,055 million to $4,170 million and EPS of $11.74 to $12.24, both initial estimates
Outlook assumes about $1.5 billion of share repurchases in 2025, subject to market conditions
IDEXX's board approved a new unfunded deferred compensation plan on December 6, 2024, letting select management and highly compensated employees defer part of their pay. The filing describes the plan's terms but gives no financial figures for its cost or expected size, and it is a compensation arrangement rather than a change in leadership.
Board approved the IDEXX Deferred Compensation Plan on December 6, 2024, on the Compensation and Talent Committee's recommendation.
Participants may defer 5% to 50% of base salary and 5% to 100% of annual bonus and stock units.
The Company has no current intention to make discretionary contributions to participant accounts.
Full plan document will be filed as an exhibit to the 2024 Form 10-K.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Idexx Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →